IL2 and breast carcinoma: The production of IL-2 was first connected to breast cancer progression in patients treated for breast cancer who had a relapse percentage of 4.7% if the IL-2 plasmatic level was normal while the relapse percentage increased to 33.3% if IL-2 was low after a 10-12 month follow-up [11].